However, NSCLC patients, whose tumour samples had strong E-cadherin cancer cell staining by immunohistochemistry, had a significantly longer time to progression and a trend to increased overall survival, when treated with the combination of erlotinib plus chemotherapy as compared with chemotherapy alone (Yauch et al, 2005). The gene discussed is CDH1; the disease is cancer.